Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 20:36:33时区推断·⟳ 抓取 20:38:10·⚡ 决策 08-04 22:23:10 +1h45m·84.0 天前
Nuwellis拟把Aquadex扩展为更广体外治疗平台
公司披露的是研发阶段平台扩展计划，相关适应场景尚未获FDA批准、许可或商业销售。
📄 原文Investing.com↗ 原文
Nuwellis plans to expand Aquadex system capabilities
BofA says this memory stock could double. Here are 5 reasons why MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) announced t…
不做 Nuwellis（NUWE.US）
研发阶段产品路线，未获批、未商业化、无订单和量级，无法形成正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 公司披露的是研发阶段平台扩展计划，相关适应场景尚未获FDA批准、许可或商业销售。
主要风险
- 没有临床数据、监管批准、商业化时间表或订单金额，短线业绩增量无法量化。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 2,004 字
BofA says this memory stock could double. Here are 5 reasons why
MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) announced today strategic development initiatives to expand its Aquadex SmartFlow System into a broader extracorporeal therapy platform, according to a press release statement.
The medical technology company said the program aims to enhance the system’s operating parameters by supporting higher blood flow rates, expanded operating pressure ranges, and broader compatibility with advanced extracorporeal therapies. The initiative is designed to create a foundation for future therapeutic applications beyond ultrafiltration.
The company stated the expanded platform is intended to address additional critical care applications, including blood purification, immunomodulation and extracorporeal life support. Nuwellis said the broader platform is anticipated to enable strategic collaborations with developers of blood purification and other extracorporeal therapies.
"We believe Aquadex has the potential to evolve from a differentiated ultrafiltration system into a versatile extracorporeal therapy platform," said Mike McCormick, Nuwellis President and Chief Executive Officer.
The Aquadex SmartFlow System is currently indicated for continuous ultrafiltration therapy for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics.
The company noted that the development initiatives are research-stage applications currently in development and are not yet approved, cleared, or licensed by the U.S. Food and Drug Administration. They are not currently available for commercial sale, distribution, or clinical use.
Nuwellis said it expects to provide future updates regarding technical milestones, regulatory strategy, and commercialization plans as the program progresses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
MINNEAPOLIS - Nuwellis, Inc. (NASDAQ:NUWE) announced today strategic development initiatives to expand its Aquadex SmartFlow System into a broader extracorporeal therapy platform, according to a press release statement.
The medical technology company said the program aims to enhance the system’s operating parameters by supporting higher blood flow rates, expanded operating pressure ranges, and broader compatibility with advanced extracorporeal therapies. The initiative is designed to create a foundation for future therapeutic applications beyond ultrafiltration.
The company stated the expanded platform is intended to address additional critical care applications, including blood purification, immunomodulation and extracorporeal life support. Nuwellis said the broader platform is anticipated to enable strategic collaborations with developers of blood purification and other extracorporeal therapies.
"We believe Aquadex has the potential to evolve from a differentiated ultrafiltration system into a versatile extracorporeal therapy platform," said Mike McCormick, Nuwellis President and Chief Executive Officer.
The Aquadex SmartFlow System is currently indicated for continuous ultrafiltration therapy for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics.
The company noted that the development initiatives are research-stage applications currently in development and are not yet approved, cleared, or licensed by the U.S. Food and Drug Administration. They are not currently available for commercial sale, distribution, or clinical use.
Nuwellis said it expects to provide future updates regarding technical milestones, regulatory strategy, and commercialization plans as the program progresses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。